The Federal Trade Commission (FTC) has intensified its scrutiny of pharmaceutical companies’ patent practices, particularly concerning the listing of patents in the Food and Drug Administration’s (FDA) Orange Book. This registry is pivotal for generic drug manufacturers, as it outlines patents associated with approved drugs. The FTC’s concern is that some companies may be listing patents improperly, potentially delaying the entry of more affordable generic alternatives into the market.
In November 2023, the FTC issued warning letters to ten pharmaceutical companies, challenging the legitimacy of over 100 patents listed in the Orange Book. The agency argued that these listings could unjustly delay generic competition, leading to higher drug prices for consumers. In response, at least three companies—GlaxoSmithKline (GSK), Impax Laboratories, and Kaléo—chose to delist certain patents. GSK, for instance, removed patents related to its Arnuity Ellipta inhaler and other products, while maintaining that the patents remain “valid and enforceable.” ([benefitspro.com](https://www.benefitspro.com/2024/01/02/ftc-scrutiny-leads-glaxosmithkline-and-2-other-drugmakers-to-delist-patents/?utm_source=openai))
However, not all pharmaceutical companies have complied with the FTC’s requests. A review indicated that eight companies, including Novo Nordisk and GSK, opted to retain their contested patents in the Orange Book. Novo Nordisk, facing challenges to 17 patents for its diabetes medication Ozempic, stated that its listings are “appropriate and in compliance with applicable law, regulations, and guidance.” ([fiercepharma.com](https://www.fiercepharma.com/pharma/drugmakers-dig-their-heels-amid-ftcs-latest-patent-challenges-what-could-come-next?utm_source=openai))
The FTC’s actions are part of a broader effort to address practices that may hinder competition and keep drug prices elevated. The agency has also taken steps to block mergers that could reduce competition. For example, in May 2023, the FTC sued to prevent Amgen’s $27.8 billion acquisition of Horizon Therapeutics, expressing concerns that the merger would allow Amgen to leverage its portfolio to stifle competition for Horizon’s drugs. ([thehill.com](https://thehill.com/policy/healthcare/monopoly-concerns-push-ftc-to-sue-to-block-amgens-more-than-26b-deal-for-horizon/?utm_source=openai))
These developments underscore the ongoing tension between regulatory bodies aiming to promote competition and pharmaceutical companies seeking to protect their intellectual property and market share. The outcomes of these disputes will likely have significant implications for drug pricing and the availability of generic medications in the United States.